This acquisition brings together two innovators in the electrophoresis space. Advances in genomics, metabolomics, and proteomics are driving growth and demand for robust, purpose built solutions to analyze biomolecules such as nucleic acids (RNA and DNA), proteins, carbohydrates and small molecules. AATI has developed compelling products based on CE technologies that provide key advances in sensitivity and resolution to address a wide range of applications across a variety of industry segments.
“We are pleased to announce that the transaction is now complete, and we are looking forward to integrating the teams,” said Sam Raha, president of Agilent’s Diagnostics and Genomics Group. “This acquisition enhances Agilent’s existing expertise and technology base, and will allow us to provide customers with a more comprehensive set of solutions for Next Generation Sequencing (NGS) workflows and also for other applications.”
AATI’s 109 employees with join Agilent as part of the new Biomolecular Analysis Division within its Diagnostics and Genomics Group. The new Biomolecular Analysis Division will also consist of Agilent’s existing microfluidics business, which was previously part of Agilent’s Life Sciences and Applied Markets Group.
Forward-Looking Statements
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent’s future revenue, earnings and profitability; planned new products; market trends; the future demand for the company’s products and services; customer expectations; and revenue and non-GAAP earnings guidance for the third quarter and full fiscal year 2018. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on our operations, our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended April 30, 2018. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.
Contacts
EDITORIAL CONTACTS:
Agilent Technologies:
Victoria Wadsworth-Hansen (Business), +1 408-553-2005
+ 45 29336980
victoria.wadsworth-hansen@agilent.com
or
Stefanie Notaney (Enterprise), +1 408-345-8955
stefanie.notaney@agilent.com
or
INVESTOR CONTACT:
Alicia Rodriguez, +1 408-345-8948
alicia_rodriguez@agilent.com
